Harmony Biosciences Holdings Stock News

PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (" Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare

California State Teachers Retirement System raised its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 227.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,786 shares of the companys stock after acquiring an additional 21,393 shares during the quarter. California State []

PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare

Marshall Wace North America L.P. lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 66,761 shares of the companys stock after selling 22,186 shares during the quarter. Marshall Wace North America L.P. owned approximately []

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Director Andreas Wicki sold 1,417 shares of Harmony Biosciences stock in a transaction on Wednesday, November 17th. The shares were sold at an average price of $41.25, for a total transaction of $58,451.25. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC []

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Director Andreas Wicki sold 35,600 shares of the businesss stock in a transaction dated Monday, November 15th. The stock was sold at an average price of $42.08, for a total transaction of $1,498,048.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. []

Analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to post $89.83 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Harmony Biosciences earnings. The highest sales estimate is $91.70 million and the lowest is $88.90 million. Harmony Biosciences posted sales of $56.29 million during the same quarter last []

Harmony Biosciences (NASDAQ:HRMY) and Amarantus BioScience (OTCMKTS:AMBS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations. Risk & Volatility Harmony Biosciences has a beta of -0.27, suggesting that its stock price is []

Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q3 2021 Results - Earnings Call Transcript

PLYMOUTH MEETING, Pa., Nov. 11, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative t

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 88.89% and 1.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead

Today, we take our first in-depth look at Harmony Biosciences who IPO'd late in 2020. The company's primary compound WAKIX is seeing impressive sales growth and Harmony is already profitable.

PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializi

Harmony Biosciences Holdings, Inc. (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving h